Most of our revenue currently comes from OTC products, and we anticipate growth from our investigational Alzheimer's drugs. In fiscal 2022, IGC-AD1, our Phase 2 drug, showed promise in reducing neuropsychiatric symptoms in Alzheimer's patients...
Relevance: 14.935795